Difference between revisions of "Oropharyngeal cancer, HPV-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
Warner-admin (talk | contribs) m (Text replacement - "|Phase III (" to "|Phase 3 (") |
||
| Line 30: | Line 30: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6541928/ Gillison et al. 2018 (RTOG 1016)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6541928/ Gillison et al. 2018 (RTOG 1016)] | ||
|2011-2014 | |2011-2014 | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
|Cetuximab & RT | |Cetuximab & RT | ||
| style="background-color:#91cf60" |Seems to have superior OS | | style="background-color:#91cf60" |Seems to have superior OS | ||
| Line 52: | Line 52: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6319250/ Mehanna et al. 2018 (De-ESCALaTE HPV)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6319250/ Mehanna et al. 2018 (De-ESCALaTE HPV)] | ||
|2012-2016 | |2012-2016 | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
|Cetuximab & RT | |Cetuximab & RT | ||
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS | ||
Revision as of 14:46, 12 February 2022
| Section editor | |
|---|---|
 |
Michael K. Gibson, MD, PhD, FACP Vanderbilt University Nashville, TN  mgibson21212 |
Note: this page has regimens which are specific to oropharyngeal cancer that is human papilloma virus (HPV) positive. Please see the head and neck cancer page for other regimens.
1 regimens on this page
2 variants on this page
|
All lines of therapy
Cisplatin & RT
| back to top |
Cisplatin & RT: Cisplatin & Radiation Therapy
Regimen variant #1, 100 mg/m2 q3wk x 2
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Gillison et al. 2018 (RTOG 1016) | 2011-2014 | Phase 3 (C) | Cetuximab & RT | Seems to have superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
21-day cycle for 2 cycles
Radiotherapy
- Concurrent radiation therapy 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 6 times per week
6-week course
Regimen variant #2, 100 mg/m2 q3wk x 3
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Mehanna et al. 2018 (De-ESCALaTE HPV) | 2012-2016 | Phase 3 (C) | Cetuximab & RT | Superior OS |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
21-day cycle for 3 cycles
Radiotherapy
- Concurrent radiation therapy 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 6 times per week
6-week course
References
- RTOG 1016: Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019 Jan 5;393(10166):40-50. Epub 2018 Nov 15. Erratum in: Lancet. 2020 Mar 7;395(10226):784. link to original article contains protocol link to PMC article PubMed NCT01302834
- De-ESCALaTE HPV: Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019 Jan 5;393(10166):51-60. Epub 2018 Nov 15. link to original article contains protocol link to PMC article PubMed ISRCTN33522080